To evaluate the relationship between daily hormone trajectories and the time to final menstrual period (FMP), focusing on the role of pregnanediol glucuronide (PDG).
Key Findings:
PDG is identified as a powerful predictor of time to FMP, contrary to previous assumptions.
Cluster analyses of PDG on the DTW/FuzzEn plane yield statistically different survival curves.
Cox proportional hazards analyses confirm the robustness of PDG's predictive power when accounting for known covariates.
Interpretation:
The study validates the DTW/FuzzEn analytical framework and introduces PDG as a significant metric in assessing ovarian aging and predicting FMP.
Limitations:
The study is based on a specific cohort from the SWAN study, which may limit generalizability.
Focus on a single menstrual cycle may not capture long-term hormonal trends.
Conclusion:
This research highlights the importance of PDG in understanding menopause timing and suggests its potential role in preventive care related to FMP.
A large Epic Cosmos analysis linked vaginal estrogen prescribing with lower rates of sepsis, hospital admission, and death following recurrent urinary tract infection, but researchers cautioned that prescribing may also mark broader differences in care.
